|
1
|
Jokhadze N, Das A and Dizon DS: Global
cancer statistics: A healthy population relies on population
health. CA Cancer J Clin. 74:224–226. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Begum S, Brait M, Dasgupta S, Ostrow KL,
Zahurak M, Carvalho AL, Califano JA, Goodman SN, Westra WH, Hoque
MO and Sidransky D: An epigenetic marker panel for detection of
lung cancer using cell-free serum DNA. Clin Cancer Res.
17:4494–4503. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7(170070)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Abu-Remaileh M, Bender S, Raddatz G,
Ansari I, Cohen D, Gutekunst J, Musch T, Linhart H, Breiling A,
Pikarsky E, et al: Chronic inflammation induces a novel epigenetic
program that is conserved in intestinal adenomas and in colorectal
cancer. Cancer Res. 75:2120–2130. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Payne SR: From discovery to the clinic:
The novel DNA methylation biomarker (m)SEPT9 for the detection of
colorectal cancer in blood. Epigenomics. 2:575–585. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Weiss G, Schlegel A, Kottwitz D, König T
and Tetzner R: Validation of the SHOX2/PTGER4 DNA methylation
marker panel for plasma-based discrimination between patients with
malignant and nonmalignant lung disease. J Thorac Oncol. 12:77–84.
2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Schneider KU, Dietrich D, Fleischhacker M,
Leschber G, Merk J, Schäper F, Stapert HR, Vossenaar ER, Weickmann
S, Liebenberg V, et al: Correlation of SHOX2 gene amplification and
DNA methylation in lung cancer tumors. Bmc Cancer.
11(102)2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Burbee DG, Forgacs E, Zöchbauer-Müller S,
Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S,
et al: Epigenetic inactivation of RASSF1A in lung and breast
cancers and malignant phenotype suppression. J Natl Cancer Inst.
93:691–699. 2001.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Din SN, Ali MN, Ganai BA, Mudassar S, Khan
MS, Kour J, Waza AA, Rasool MT and Lone AM: Association of promoter
methylation of RASSF1A and KRAS mutations in non-small cell lung
carcinoma in Kashmiri population (India). Heliyon.
6(e3488)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Feng H, Shao W, Du L, Qing X, Zhang Z,
Liang C and Liu D: Detection of SHOX2 DNA methylation by
methylation-specific PCR in non-small cell lung cancer. Transl
Cancer Res. 9:6070–6077. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Leiro V, De Chiara L, Rodríguez-Girondo M,
Botana-Rial M, Valverde D, Núñez-Delgado M and Fernández-Villar A:
Methylation assessment for the prediction of malignancy in
mediastinal adenopathies obtained by endobronchial
ultrasound-guided transbronchial needle aspiration in patients with
lung cancer. Cancers (Basel). 11(1408)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Huang W, Huang H, Zhang S, Wang X, Ouyang
J, Lin Z and Chen P: A novel diagnosis method based on methylation
analysis of SHOX2 and serum biomarker for early stage lung cancer.
Cancer Control. 27(1073274820969703)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Vizoso M, Puig M, Carmona FJ, Maqueda M,
Velásquez A, Gómez A, Labernadie A, Lugo R, Gabasa M,
Rigat-Brugarolas LG, et al: Aberrant DNA methylation in non-small
cell lung cancer-associated fibroblasts. Carcinogenesis.
36:1453–1463. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Borg M, Wen SWC, Andersen RF, Timm S,
Hansen TF and Hilberg O: Methylated circulating tumor DNA in blood
as a tool for diagnosing lung cancer: A systematic review and
meta-analysis. Cancers (Basel). 15(3959)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xie B, Dong W, He F, Peng F, Zhang H and
Wang W: The combination of SHOX2 and RASSF1A DNA methylation had a
diagnostic value in pulmonary nodules and early lung cancer.
Oncology. 102:759–774. 2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Liu J, Bian T, She B, Liu L, Sun H, Zhang
Q, Zhu J, Zhang J and Liu Y: Evaluating the comprehensive diagnosis
efficiency of lung cancer, including measurement of SHOX2 and
RASSF1A gene methylation. BMC Cancer. 24(282)2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhao J, Lu Y, Ren X, Bian T, Feng J, Sun
H, Liu L, She B, Liu Y and Ke H: Association of the SHOX2 and
RASSF1A methylation levels with the pathological evolution of
early-stage lung adenocarcinoma. BMC Cancer. 24(687)2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shi J, Chen X, Zhang L, Fang X, Liu Y, Zhu
X, Zhang H, Fan L, Gu J, Zhang S, et al: Performance evaluation of
SHOX2 and RASSF1A methylation for the aid in diagnosis of lung
cancer based on the analysis of FFPE specimen. Front Oncol.
10(565780)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Marchini A, Ogata T and Rappold GA: A
track record on SHOX: From basic research to complex models and
therapy. Endocr Rev. 37:417–448. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang M, Zhang JY, Sun MQ, Lu P and Liu
JX: Realgar (α-As(4)S(4)) treats myelodysplastic syndromes through
reducing DNA hypermethylation. Chin J Integr Med. 28:281–288.
2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Su J, Wang Y, Xing X, Liu J and Zhang Y:
Genome-wide analysis of DNA methylation in bovine placentas. BMC
Genomics. 15(12)2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Donninger H, Vos MD and Clark GJ: The
RASSF1A tumor suppressor. J Cell Sci. 120 (Pt 18):3163–3172.
2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Dubois F, Keller M, Calvayrac O, Soncin F,
Hoa L, Hergovich A, Parrini MC, Mazières J, Vaisse-Lesteven M,
Camonis J, et al: RASSF1A suppresses the invasion and metastatic
potential of human non-small cell lung cancer cells by inhibiting
YAP activation through the GEF-H1/RhoB pathway. Cancer Res.
76:1627–1640. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tomizawa Y, Iijima H, Nomoto T, Iwasaki Y,
Otani Y, Tsuchiya S, Saito R, Dobashi K, Nakajima T and Mori M:
Clinicopathological significance of aberrant methylation of
RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients
with non-small cell lung cancer. Lung Cancer. 46:305–312.
2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vo TTL, Nguyen TN, Nguyen TT, Pham ATD,
Vuong DL, Ta VT and Ho VS: SHOX2 methylation in Vietnamese patients
with lung cancer. Mol Biol Rep. 49:3413–3421. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhao QT, Guo T, Wang HE, Zhang XP, Zhang
H, Wang ZK, Yuan Z and Duan GC: Diagnostic value of SHOX2 DNA
methylation in lung cancer: A meta-analysis. Onco Targets Ther.
8:3433–3439. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ren M, Wang C, Sheng D, Shi Y, Jin M and
Xu S: Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar
lavage fluid for early lung cancer diagnosis. Ann Diagn Pathol.
27:57–61. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang C, Yu W, Wang L, Zhao M, Guo Q, Lv
S, Hu X and Lou J: DNA methylation analysis of the SHOX2 and
RASSF1A panel in bronchoalveolar lavage fluid for lung cancer
diagnosis. J Cancer. 8:3585–3591. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Vaissière T, Hung RJ, Zaridze D, Moukeria
A, Cuenin C, Fasolo V, Ferro G, Paliwal A, Hainaut P, Brennan P, et
al: Quantitative analysis of DNA methylation profiles in lung
cancer identifies aberrant DNA methylation of specific genes and
its association with gender and cancer risk factors. Cancer Res.
69:243–252. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ji XY, Li H, Chen HH and Lin J: Diagnostic
performance of RASSF1A and SHOX2 methylation combined with EGFR
mutations for differentiation between small pulmonary nodules. J
Cancer Res Clin Oncol. 149:8557–8571. 2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gao H, Yang J, He L, Wang W, Liu Y, Hu Y,
Ge M, Ding J and Ye Q: The diagnostic potential of SHOX2 and
RASSF1A DNA methylation in early lung adenocarcinoma. Front Oncol.
12(849024)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Grawenda AM and O'Neill E: Clinical
utility of RASSF1A methylation in human malignancies. Br J Cancer.
113:372–381. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Oh MH and Lockwood WW: RASSF1A
methylation, YAP1 activation and metastasis: A new role for an old
foe in lung cancer. J Thorac Dis. 9:1165–1167. 2017.PubMed/NCBI View Article : Google Scholar
|
